Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data

January 17, 2024

https://www.globenewswire.com/news-release/2024/01/16/2809668/0/en/Cellectar-Biosciences-Broadens-Pipeline-with-Targeted-Alpha-Therapy-TAT-for-Solid-Tumors-and-Releases-Promising-Preclinical-Data.html

Proprietary TAT Phospholipid Conjugate Demonstrates Potent Activity in Resistant Pancreatic Cancer

Initiating IND-enabling Studies for First-in-Human Phase I Clinical Study

Read more at globenewswire.com

Related news for (CLRB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.